



Molecular genetics of β -thalassemia in Tripoli-Libya

Marwan, M. M^{1*}, Tabagh, R. M¹, Gadmour, H, M¹, Scerri, C. A², and Felice, A, E²

1. Devision of Developmental Biology, Department of Zoology, Faculty of Science, University of Tripoli, Libya.

2. Laboratory of Molecular Genetics, Department of Pathology, Faculty of Medicine,

Corresponding author: MohamedMarwan14@gmail.com.

ARTICLE INFO

Article history:

Received: 10/11/2024

Received in revised form 25/02/2025

Accepted: 23/03/2025

ABSTRACT

β -thalassemia is an inherited blood disorder, in which the body does not make as much as β -globin as it should be. Hemoglobin is the part of a red blood cells (RBCs) that carries oxygen throughout the body. β -thalassemia includes three main forms, major, intermedia, and minor. β -globin DNA mutations present in 14 subjects from 866 adult samples. β -thalassemia, major and minor were analyzed by DNA sequencing of amplified DNA. Different β -thalassemia mutations were identified. The three common three β -thalassemia found in Libya were B⁰CD39 (C→T) N=6, B+IVS-1,6 (C→T) N=5, and B+IVS-1,110 (G→A) N=3.

Keywords: β -thalassemia, DNA Sequencing, Libyan Adults, Tripoli.

1. Introduction

Hemoglobinopathies are the most common single gene disorders. They are inherited disease effecting the structure and synthesis of globin chains. They constitute a major public health problem in the world. They can be divided into two groups, such as hemoglobin variants and thalassemia [1]. Although in Libya these disorders are thought to be common, [2], [3,4], and 1999 [5].

Thalassemia is a globin gene disorder that results in an effective rate of synthesis of one or more of the globin chains. About 1.5% of the global population (80 to 90

million) are carriers of β -thalassemia. More than 500 mutations are described as β -thalassemia. There are eight common mutations in Mediterranean countries [6]. β -thalassemia is common in Mediterranean countries Middle east, Central Asia, India, Southern China, the Far East as well as countries along the North coast of Africa and South America [7]. The highest carrier frequency is reported.

in Cyprus (14%) [8], and Sardinia (10.3%) [9]. We concluded that there are three common β -thalassemia mutations in Tripoli area B⁰ CD39 (C→T), B⁺IVS-1,6 (T→C), and B+IVS-1,110 (G→A).

2. Materials and Methods

2.1. Blood samples collection

Blood samples (5ml) were collected in vacutainers with EDTA as anticoagulant from 866 adult Libyan samples. The blood were stored at 4°C.

2.2. Hematological determination

Hematological values were obtained on a Hematology Autoanalyser System 9000 .The RBC count ($\times 10^2/L$), Hb concentration (g/dl), MCV (in fl) and MCH (in pg). The MCV, MCH and HbA₂ values were especially useful parameters in diagnosis of β -thalassemia heterozygous. The MCV below 80 fl, MCH value below 27 pg and Hb A₂ above 3.5% were a sign of the presence of β -thalassemia carrier.

2.3. Hb A₂ Quantitation

The Helena β -Thal Hb A₂ Quick column procedure (Microchromatographic method) was used for the quantitation of Hb A₂. The accurate Quantitation of Hemoglobin A₂ (HbA₂) is essential for diagnosis of several anemias and elevated Hb A₂ is widely regarded as efficient evidence for the diagnosis of β -thalassemia trait.

2.4. DNA isolation from whole blood (Micro Method)

This method had been described by Saiki et al 1986. The DNA was stored at -20°C. The yield of a genomic DNA was equivalent to one microgram, in 25ul of lysate.

2.5. Agarose gel electrophoresis

The standard method used to separate, identify and purify DNA fragments was electrophoresis through agarose gel. The technique was simple, rapid to perform and capable of resolving mixture of fragments. The location of DNA within the gel could be

determined directly. Bands of DNA with gel were stained with low Concentrations of the fluorescent intercalating dye ethidium bromide. As little as μg of DNA can then be detected by direct examination of gel in ultraviolet light.

2.6. PCR using tbr polymerase

The amplification of genomic DNA was performed on automated thermal cycler (Perkin Elmer, Norwalk CT, USA [10] and [11] . The DNA was subsequently stored at -20°C until further use.

2.7. Direct Sequencing of PCR Amplified DNA

DNA sequencing information has led to many major advances in molecular Biology. The accurate determination of the nucleotide sequence of DNA is often an essential part of the analysis of the structure and function of genes. The two main sequencing techniques in current are the chemical degradation method of [12] and the Enzymatic method of Sanger [13].

3. Results and Discussion

3.1. Molecular pathology of β -Thalassemia

Hematological data for all 14 cases with β -Thalassemia, (4 patients and 10 anaemic heterozygotes) from screening are summarized in table 1. The ages between 22 and 28 years, RBC were between 3.45 and $6.0 \times 10^2/L$, Hemoglobin value ranged from 6.9 and 11.4 g/dl. The MCV value were variable between 45.6 and 74.5 fl, while the MCH values were between 16.7, 24.1pg and Hb A₂ were between 3.2% and 6.2%.

Table .1. hematological and Hb computation of 14 β -thalassemia from screening studies. (aljala Hospital

Tripoli-Libya

Case	Gender-years	RBC10 ¹² /L	Hb g/dl	MCV fl	HCH pg	Hb A ₂ %	HB –A %	Hb F %	Genotypes
LA320*	F- 25	5.69	11.4	65.4	20.0	5.4	61.4	33.2	CD39T/B ^A
LA431*	F- 25	3.9	7.8	62.1	20.0	4.5	63.3	32.2	CD39T/B ^A
LA521*	F- 28	5.76	11.1	59.4	19.3	4.9	85.1	10.0	CD39T/B ^A
LA661*	F- 30	5.50	9.2	54.6	16.7	6.2	84.7	9.1.	CD39T/B ^A
LA783*	F- 32	4.88	9.2	61.6	19.2	5.2	82.3	11.1	CD39T/B ^A
LA866*	F- 37	5.00	12.6	68.4	19.8	5.3	8.5	10.1	CD39T/B ^A
LA630*	F- 22	3.5	7.1	67.3	21.4	6.1	74.9	14.8	IVS-1,6C/IVS-I,6C
LA211*	F- 26	3.62	7.7	68.5	21.2	3.5	74.2	19.7	IVS-1,6C/IVS-1,6C
LA115*	F- 27	3.45	7.5	24.1	3.5	3.5	71.0	14.9	IVS-1,6C/IVS-1,6C
LA189*	F- 28	3.46	7.3	72.6	21.1	5.5	80.0	4.9	IVS-1,6C/IVS-1,6C
LA190*	F- 34	6.07	12.1	66.0	19.5	4.9	68.0	26.5	IVS-1,6C/IVS-1,6C
LA75*	F- 26	4.88	9.6	60.2	19.7	4.0	68.1	27.0	IVS-1,110A/B ^A
LA801*	F- 24	4.76	6.9	64.4	18.8	5.2	86.7	9.3	IVS-1,110A/B ^A
LA585*	F-24	5.35	10.8	63.9	20.3	5.2	85.0	10.0	IVS-1,110A/B ^A

* LA Libyan Adult

3.2. DNA Sequencing

The determination of the sequence of the amplified DNA samples (suving dideoxy method) contained the β -globin gene of 14 β -thalassemia. All samples were sequenced and the type of mutation was determined, Five sample which B⁺IVS-1,6 (C), gave the sequence C at position number 6 of B-IVS-1 instead of T for both homozygotes and heterozygotes (fig 3.1).



Fig. 3.1. Sequencing gel of the emplified of β -globin gene IVS,1,6, T→C homozygote

Three samples which were B⁺IVS-I,110 (A) heterozygotes gave the sequence A at position number 110 of B⁺IVS-I,110 Instead of G (fig3.2).



Fig.3.2. Sequencing gel of the amplified β -globin gene IVS, 1,110 C→A heterozygote

Six which were B⁰CD39T heterozygotes gave C-T mutation in codon 39 (CAG for Gln to TAG for Stop) as indicated in appropriate section of the sequencing film (Fig 3.3).




Fig.3.3. Sequencing of amplified codon 39 C-T heterozygote

4. Discussion

Molecular characterization of the β -thalassemia mutations:

The characterization of the β -thalassemia defection of 19 chromosomes has shown great molecular heterogeneity with 3 different mutations being observed. These three mutations are B⁰ CD39 (C→T), B⁺IVS-1,6 (T→C), and B⁺IVS-1,110 (G→A). These data support the general observation that in most populations. A few mutation

(8 or less) account for most of β -thalassemia mutations [14].

The most common mutations in Libya is B⁺IVS-1,6 (T→C), is famous in about 35,7% (N= 5) of these three mutations. It is prevalent in many Mediterranean countries, being the most common mutation in Malta and account for 71,4% [15], and is the second most common mutation in Libya. The nonsense mutation B⁰ CD39 (C→T), is found in 42,8% (N=6), and is the most prevalent in many West and Central Mediterranean countries such Algeria [16], Italy [17], and Algeria [18], this mutations reaches its heighest frequency in Sardinia 95,7% [19].

The third most common mutations in Libya is B⁺IVS-1,110 (G→A), this mutation effects RNA processing and is found in about 21,5% (N=3). This mutation is the most prevalent in many East Mediterreanan countries ,such as Egypt [16] (Khan et al. 2021), Greece (Voskarida et al. 2019) [20], Italy[9], Lebanon 62% [18], and Cyprus where reached the highest at 77% (Bozkurt, 2007)[8].

5. Reffrences

1. Weatherall, D. J. and Clegg, J. B.: The thalassaemia Syndromes, 4rd edition, Blackwell Scientific Publication, Oxford, 2001.
2. Jain, R. C. Sickle Cell and thalassamia genes in Libya, Trans Royal Society Tropical, Medicine Hygeine. 99:132, 1985.
3. Sheriff, D. S., El-Fakhri, M., Ghwarsha, K., Mutardi, K., and Boxi, A. J.: A profile of abnormal haemoglobins in Eastern and Southern Libya, Saudi Medical Journal, 10 (2): 138, 1989.
4. Regeai, S. O., Marwan, M. M., Alansari, O. A. and Felice, A. E.: The incidence of haemoglobinopathies in Tripoli, Western and Southern regions of Libya. Proceeding of the

- 6th International Conference on Talassaemia and the Haemoglobinopathies, Qawra, Malta, 1997.
5. Marwan, M. M., Scerri, C. A., Zarroag, S. O., Cao, A., Rosatall, M.C., Kyrri, A., Kalogirou, M., Ioannoa, P., Angastiniotis, M., and Felice, A. E., Comparative in vivo expression of B⁺-thalassaemia alleles. *Hemoglobin*, 23 (3): 221-228, 1999.
 6. Jha, R., and Jha, S., Beta-thalassaemia, a Review *Journal of Pathology of Nepal*, 4 (8): 663-671, 2014.
 7. Vichinsky, E. P., Changing patterns of thalassaemia *Annals of the New York Academy of Sciences* 1054 (1): 18-24, 2005.
 8. Bozkurt, G., Results from the North Cyprus thalassaemia prevention program. *Hemoglobin* 31 (2): 257-264, 2007.
 9. Cao, A., Rosatelli, M. C., and Galenello, R., Control of β -thalassaemia by carrier screening genetic counselling and prenatal diagnosis. *Symposium 197- Variation in Human Genome*, 137-155, 2007.
 10. Mullis, K. B., Faloona, F. A., Scharf, S. J., Horn, G. T., and Erlick, H. A.: Specific enzymatic amplification of DNA in Vitro: The polymerase chain reaction, *Cold Spring Hrbor. Quantatntive Biology*. 51 : 263, 1986.
 11. Saiki, R. K., Bugawan, T. L., Horn, G. T., Mullis, K. B., and Erlich, H. A., Analysis of enzymatically amplified β -globin and HLA-DQ α DNA with allele-specific oligonucleotide, *Probes, Nature*, 324: 163, 1986.
 12. Maxam, A. H., and Gilbert, W.: A new method for Sequencing DNA, *Proceeding National Academy of Science, USA*, 74: 560, 1977.
 13. Sanger, F.: Determination of Nucleotide Sequences in DNA, *Science*, 214: 1205, 1981.
 14. Cao, A., and Galanell, O., Beta-thalassaemia. *Genetic Medicine*. 12(2): 61-76, 2010.
 15. Scerri, C. A., Clinical and Molecular pathology of the B⁺ IVS-I-6 thalassaemia in Malta, PhD thesis, 1998.
 16. Belhani, M., Epidemiology of homozygous β -thalassaemia in Africa. *Review Algerian Hematology*. 1:22, 2009.
 17. Origa, R., Piga, A., Quarta, G., Forni, G. L., Longo, F., Melpignano, A., and Gelanejjo, R., Pregnancy and β -thalassaemia: a Multicenter Experience, *Haematologica* 95 (3): 376-381, 2010.
 18. khan, A. M., Al-Sulalti, A. M., Younes, S., Yassin, M., and Zayed, H., The spectrum of beta-thalassaemia mutations in the 22-Arab Countries, *Systematec Review Expert, Review Hematology*, 14(1): 109-122, 2021.
 19. Maxam, A. H., and Gilbert, W.: A new method for Sequencing DNA, *Proceeding National Academy of Science, USA*, 74: 560, 1977.
 20. Voskaridu, E., Rattamis, A, Fragodimitric, et al. And Papassotiriou, I., Greek haematolobinopatces Study group, National Registry updated dermographic of Mortality, *Annual haematology* 98 (1): 55-66, 2019.